| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
Myricetin 3-O-glucoside targets Leishmania parasites, exhibiting anti-Leishmanial activity. It also modulates inflammatory pathways and exerts antimicrobial effects. As a flavonol glycoside, it may interact with various cellular targets including kinases, transcription factors, and enzymes involved in oxidative stress and inflammation. The glycosylation at the 3-position affects its target interactions and bioavailability compared to the myricetin aglycone.
|
|---|---|
| ln Vitro |
Myricetin 3-O-glucoside exhibits anti-Leishmanial activity against Leishmania parasites, anti-inflammatory activity, and antimicrobial activity against various pathogens. Its anti-Leishmanial activity is attributed to its ability to interfere with parasite growth and survival. The anti-inflammatory activity likely involves inhibition of pro-inflammatory mediators and modulation of immune responses. Antimicrobial effects are observed against a range of bacteria and fungi. Detailed IC₅₀ values are not extensively documented.
|
| ln Vivo |
In vivo activity data for Myricetin 3-O-glucoside are limited in the available literature. Based on its in vitro anti-Leishmanial, anti-inflammatory, and antimicrobial activities, it is anticipated to have potential in vivo efficacy in animal models of Leishmaniasis, inflammation, or infection. However, specific in vivo studies detailing its therapeutic effects and pharmacokinetics are not extensively documented.
|
| Enzyme Assay |
The non-cellular enzyme/receptor binding assays for Myricetin 3-O-glucoside would typically involve evaluating its antioxidant activity using chemical assays such as DPPH, ABTS, and FRAP. Its ability to scavenge free radicals is measured spectrophotometrically. Anti-inflammatory activity can be assessed using enzyme inhibition assays for COX-1, COX-2, and LOX. The compound is incubated with the enzyme and substrate, and the inhibition of product formation is measured. Anti-Leishmanial activity is evaluated using parasite-based assays.
|
| Cell Assay |
In vitro cellular assays for Myricetin 3-O-glucoside typically involve testing its anti-Leishmanial activity against Leishmania parasites in infected macrophage cultures. Macrophages are infected with Leishmania amastigotes and treated with various concentrations of the compound. Parasite load is determined by counting intracellular parasites or by measuring parasite-specific markers. Anti-inflammatory activity is evaluated using LPS-stimulated macrophages, measuring nitric oxide, cytokine production, and inflammatory marker expression. Antimicrobial activity is assessed using broth microdilution assays.
|
| Animal Protocol |
In vivo animal studies for Myricetin 3-O-glucoside are not extensively documented. Based on its anti-Leishmanial activity, typical study designs would involve mouse models of cutaneous or visceral Leishmaniasis. The compound would be administered orally or intraperitoneally. Parasite burden in target organs, lesion size (for cutaneous), and immune responses would be evaluated. Efficacy would be compared to standard anti-Leishmanial drugs.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Myricetin 3-O-glucoside are not extensively characterized. As a glycosylated flavonol, it is expected to have limited oral bioavailability due to poor membrane permeability and extensive metabolism. The glucose moiety may be hydrolyzed by intestinal glucosidases, releasing the myricetin aglycone. Metabolic pathways likely involve phase II conjugation (glucuronidation and sulfation) of the phenolic hydroxyl groups. Specific PK parameters such as half-life, Cmax, and bioavailability are not well documented.
|
| Toxicity/Toxicokinetics |
Toxicological data for Myricetin 3-O-glucoside are limited. As a naturally occurring flavonoid glycoside, it is generally considered to have low toxicity. However, comprehensive toxicology studies are not available. The compound may cause skin and eye irritation upon contact. Standard laboratory safety precautions should be observed when handling this compound.
|
| References | |
| Additional Infomation |
Myricetin-3-O-β-D-glucopyranoside is a myricetin O-glucoside, i.e., myricetin with a β-D-glucosyl residue linked at the 3-position. It is a plant metabolite. It is a myricetin O-glucoside, β-D-glucoside, monosaccharide derivative, and penthydroxyflavonoid. Its function is related to β-D-glucose. It is the conjugate acid of myricetin-3-O-β-D-glucopyranoside (1-). Myricetin-3-O-β-D-glucopyranoside has been reported in tea (Camellia sinensis), small-flowered windmill (Combretum micranthum), and other organisms with relevant data. Myricetin-3-O-glucoside is a metabolite found or produced in Saccharomyces cerevisiae. See also: Myricetin-3-glucoside (note moved to).
Myricetin 3-O-glucoside is a research-grade natural product intended for laboratory use only. It is not approved for clinical use as a therapeutic agent. Its primary applications include studying the biological activities of flavonoid glycosides, investigating anti-Leishmanial, anti-inflammatory, and antimicrobial mechanisms, and exploring structure-activity relationships of myricetin derivatives. It serves as a valuable tool for natural product and pharmacognosy research. |
| Molecular Formula |
C21H20O13
|
|---|---|
| Molecular Weight |
480.376
|
| Exact Mass |
480.09
|
| CAS # |
19833-12-6
|
| PubChem CID |
5318606
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
0
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
34
|
| Complexity |
777
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C1=C(C=C(C(=C1O)O)O)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O
|
| InChi Key |
FOHXFLPXBUAOJM-LIBJPBHASA-N
|
| InChi Code |
InChI=1S/C21H20O13/c22-5-12-15(28)17(30)18(31)21(33-12)34-20-16(29)13-8(24)3-7(23)4-11(13)32-19(20)6-1-9(25)14(27)10(26)2-6/h1-4,12,15,17-18,21-28,30-31H,5H2/t12-,15-,17+,18-,21+/m1/s1
|
| Chemical Name |
5,7-dihydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-(3,4,5-trihydroxyphenyl)chromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0817 mL | 10.4084 mL | 20.8169 mL | |
| 5 mM | 0.4163 mL | 2.0817 mL | 4.1634 mL | |
| 10 mM | 0.2082 mL | 1.0408 mL | 2.0817 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
